Prognostic factors in CLL.

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI:10.1038/leusup.2012.17
M Ferrarini, G Cutrona, A Neri, F Morabito
{"title":"Prognostic factors in CLL.","authors":"M Ferrarini,&nbsp;G Cutrona,&nbsp;A Neri,&nbsp;F Morabito","doi":"10.1038/leusup.2012.17","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for treatment. This heterogeneity of clinical course was somehow unexplained until studies on the CLL cell features disclosed that the CLL clones were heterogeneous and were characterized by different phenotypic and genotypic features in the different patients. On the basis of these observations, it was determined in retrospective studies that clones characterized by unmutated IGHV genes, and/or CD38 and/or ZAP-70 expression conferred a more severe prognosis to the CLL patients. Here, we present data on prospective studies carried out on Binet A-stage patients, in whom the markers were determined at diagnosis and their predictive value was assessed in comparison with chromosomal abnormalities and gene expression or micro RNA profiles. In addition, hypothesis on the potential pathogenetic role of these markers will be presented. </p>","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S29-30"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.17","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/leusup.2012.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for treatment. This heterogeneity of clinical course was somehow unexplained until studies on the CLL cell features disclosed that the CLL clones were heterogeneous and were characterized by different phenotypic and genotypic features in the different patients. On the basis of these observations, it was determined in retrospective studies that clones characterized by unmutated IGHV genes, and/or CD38 and/or ZAP-70 expression conferred a more severe prognosis to the CLL patients. Here, we present data on prospective studies carried out on Binet A-stage patients, in whom the markers were determined at diagnosis and their predictive value was assessed in comparison with chromosomal abnormalities and gene expression or micro RNA profiles. In addition, hypothesis on the potential pathogenetic role of these markers will be presented.

CLL的预后因素。
慢性淋巴细胞白血病(CLL)是一种临床异质性疾病,一些患者进展迅速,进入更深入的研究,而另一些患者可以在不需要治疗的情况下存活很长时间。这种临床过程的异质性在某种程度上是无法解释的,直到对CLL细胞特征的研究揭示了CLL克隆是异质性的,并且在不同的患者中具有不同的表型和基因型特征。在这些观察的基础上,在回顾性研究中确定,以未突变的IGHV基因和/或CD38和/或ZAP-70表达为特征的克隆给CLL患者带来更严重的预后。在这里,我们提供了对Binet a期患者进行的前瞻性研究的数据,在这些患者中,在诊断时确定标志物,并通过与染色体异常和基因表达或微RNA谱的比较来评估其预测价值。此外,对这些标志物的潜在致病作用的假设将被提出。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信